Ongoing and future trials of biologic therapies in lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Clinical Trials

Background:

• Lung cancer is the leading cause of cancer-related mortality worldwide.
• Current treatments like surgery, radiotherapy, and chemotherapy have limited efficacy, with a 5-year survival rate rarely exceeding 15%.
• Systemic metastases are a primary cause of death in lung cancer patients.

Purpose of the Study:

• To review current and proposed clinical trials for novel targeted therapies in lung cancer.
• To highlight the impact of molecular advances on developing new lung cancer treatments.
• To provide an overview of therapeutic strategies for both small cell and non-small cell lung cancer.

Main Methods:

• Literature review of current and proposed clinical trials.
• Analysis of molecular advances in lung cancer therapy.
• Description of targeted agents for small cell and non-small cell lung cancer.

Main Results:

• Chemotherapy offers limited survival benefits with few complete responses.
• Numerous new targeted agents have been developed based on molecular advances.
• Various clinical trials are investigating these novel therapies for lung cancer.

Conclusions:

• Targeted therapies represent a promising frontier in lung cancer treatment.
• Ongoing and proposed trials are crucial for evaluating the efficacy of these new agents.
• Advances in molecular understanding are driving the development of more effective lung cancer therapies.